



MotherToBaby

Medications & More During Pregnancy & Breastfeeding
Ask The Experts

Fact Sheet

by the **Organization of Teratology Information Specialists (OTIS)**

For more information about us or to find a service in your area,
call **(866) 626-6847**. Visit us online at **www.MotherToBaby.org**.

Find us! Facebook.com/MotherToBaby or @MotherToBaby on Twitter

Isotretinoin

Selected References

- Adams J and Lammer EJ. 1991. Relationship between dysmorphism and neuropsychological function in children exposed to isotretinoin “in utero”. In: T. Fujii and G. J. Boer (eds), *Functional Neuroteratology of Short Term Exposure to Drugs*. Tokyo: Teikyo University Press, pp.159-170.
- Adams J and Lammer EJ. 1993. Neurobehavioral teratology of isotretinoin. *Reprod Toxicol*. 7(2):175-177.
- Adams J. 1996. Similarities in genetic mental retardation and neuroteratogenic syndromes. *Pharmacol Biochem Behav*. 55(4):683-690.
- Autret-Leca E et al. 2010 Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France. *Drug safety : an international journal of medical toxicology and drug experience*. 33(8):659-665.
- Coleman, R and MacDonald D. 1994. Effects of isotretinoin on male reproductive system. *Lancet* 344:198.
- Committee on Drugs, American Academy of Pediatrics. 1992. Retinoid therapy for severe dermatological disorders. *Pediatrics* 90:119-120.
- Dai WS, et al. 1989. Safety of pregnancy after discontinuation of isotretinoin. *Arch Dermatol* 125:362-365.
- Dai WS, et al. 1992. Epidemiology of isotretinoin exposure during pregnancy. *J Am Acad Dermatol* 26:599-606.
- DiGiovanna JJ, et al. 1984. Etretinate: persistent serum levels of a potent teratogen. *Clin Res* 32:579A.
- Goldsmith LA, et al. 2004. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. 1: *J Am Acad Dermatol* 50(6):900-906. [Erratum in: *J Am Acad Dermatol*. 2004 51(3):348. dosage error in text.]
- Lammer EJ, et al. 1987. Risk for major malformation among human fetuses exposed to isotretinoin (13-cis-retinoic acid). *Teratology* 35:68A.
- Lammer EJ, et al. 1985. Retinoic acid embryopathy. *New Engl J Med* 313:837841.
- Lee SM et al. 2009. A case of suspected isotretinoin-induced malformation in a baby of a mother who became pregnant one month after discontinuation of the drug. *Yonsei medical journal*.50(3):445-447.
- Loureiro KD et al. 2005 Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. *American journal of medical genetics. Part A*. 136(2):117-121.
- Mitchell AA. 1992. Oral retinoids: What should the prescriber know about their teratogenic hazards among women of child-bearing potential? *Drug Saf* 7(2):7985.
- Nulman I. 1998. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. *J Clin Pharmacol* 38:926-930.
- Recommendations for isotretinoin use in women of childbearing potential. 1991. *Teratology* 44:1-6.
- Rosa FW. 1983. Teratogenicity of isotretinoin. *Lancet* 2:513.
- Sladden MJ. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? *Archives of dermatology*.143(9):1187-1188.
- Zakhem GA. 2019. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review. *J Am Acad Dermatol Apr*;80(4):957-969.
- [cited 2014 August 12]. Available at URL: <https://www.ipledgeprogram.com/AboutiPLEDGE.aspx>.

October, 2019